Details of the Drug

General Information of Drug (ID: DM51FY6)

• Drug Name: Tacrine
• Synonyms: Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Approved	[1], [2]

• Therapeutic Class: Parasympathomimetics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 198.26
  Topological Polar Surface Area (xlogp); 2.7
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 17% [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 56 mL/min/kg [5]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 4 hours [5]
  Metabolism: The drug is metabolized via the hepatic [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.5283 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.25% [5]
  Vd: The volume of distribution (Vd) of drug is 349 +/- 193 L [7]
• Chemical Identifiers:
  Formula: C13H14N2
  IUPAC Name: 1,2,3,4-tetrahydroacridin-9-amine
  Canonical SMILES: C1CCC2=NC3=CC=CC=C3C(=C2C1)N
  InChI: InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)
  InChIKey: YLJREFDVOIBQDA-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 1935
  ChEBI ID: CHEBI:45980
  CAS Number: 321-64-2
  DrugBank ID: DB00382
  TTD ID: D0E6YQ
  VARIDT ID: DR00183
  INTEDE ID: DR1523

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Glutathione S-transferase alpha-1 (GSTA1)	DE4ZHS1	GSTA1_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[11]

Molecular Expression Atlas of This Drug

• The Studied Disease: Alzheimer disease
• ICD Disease Classification: 8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Acetylcholinesterase (AChE)	DTT	ACHE	6.39E-02	-1.07	-1.15
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.54E-01	1.95E-01	4.04E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02
Glutathione S-transferase alpha-1 (GSTA1)	DME	GSTA1	5.78E-01	3.39E-02	1.54E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tacrine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[49]
Bethanechol	DMCLHO0	Moderate	Additive cholinergic effects by the combination of Tacrine and Bethanechol.	Abnormal micturition [MF50]	[50]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Midostaurin.	Acute myeloid leukaemia [2A60]	[51]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Idarubicin.	Acute myeloid leukaemia [2A60]	[51]
Daunorubicin	DMQUSBT	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[51]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[51]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Oliceridine.	Acute pain [MG31]	[49]
Scopolamine	DMOM8AL	Moderate	Antagonize the effect of Tacrine when combined with Scopolamine.	Addictive disorder [6C50-6C5Z]	[52]
Mepyramine	DMB4SFH	Moderate	Antagonize the effect of Tacrine when combined with Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[53]
Phenyltoloxamine	DMKAEQW	Moderate	Antagonize the effect of Tacrine when combined with Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[53]
Metronidazole	DMTIVEN	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Metronidazole.	Amoebiasis [1A36]	[51]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[54]
Hydroxyzine	DMF8Y74	Moderate	Antagonize the effect of Tacrine when combined with Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[52]
Cilostazol	DMZMSCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Cilostazol.	Arterial occlusive disease [BD40]	[51]
Voriconazole	DMAOL2S	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Voriconazole.	Aspergillosis [1F20]	[51]
Posaconazole	DMUL5EW	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Posaconazole.	Aspergillosis [1F20]	[51]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Terbutaline.	Asthma [CA23]	[51]
Aminophylline	DML2NIB	Moderate	Increased plasma concentrations of Tacrine and Aminophylline due to competitive inhibition of the same metabolic pathway.	Asthma [CA23]	[55]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Salbutamol.	Asthma [CA23]	[49]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Tacrine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[56]
Desipramine	DMT2FDC	Moderate	Antagonize the effect of Tacrine when combined with Desipramine.	Attention deficit hyperactivity disorder [6A05]	[52]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Tacrine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[57]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[51]
Clarithromycin	DM4M1SG	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[51]
Gemifloxacin	DMHT34O	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Telithromycin	DMZ4P3A	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[49]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Retigabine.	Behcet disease [4A62]	[49]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Tacrine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[58]
Loperamide	DMOJZQ9	Moderate	Antagonize the effect of Tacrine when combined with Loperamide.	Bowel habit change [ME05]	[52]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Eribulin.	Breast cancer [2C60-2C6Y]	[51]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[51]
Toremifene	DMQYUWG	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Toremifene.	Breast cancer [2C60-2C6Y]	[51]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Bosutinib.	Breast cancer [2C60-2C6Y]	[51]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[51]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Oxaliplatin.	Colorectal cancer [2B91]	[51]
Halothane	DM80OZ5	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Halothane.	Corneal disease [9A76-9A78]	[51]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Tacrine and Propofol.	Corneal disease [9A76-9A78]	[59]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Sevoflurane.	Corneal disease [9A76-9A78]	[51]
Clofazimine	DMEBOFW	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Clofazimine.	Crohn disease [DD70]	[49]
Mifepristone	DMGZQEF	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Mifepristone.	Cushing syndrome [5A70]	[51]
Pasireotide	DMHM7JS	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Pasireotide.	Cushing syndrome [5A70]	[51]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Tacrine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[60]
Sertraline	DM0FB1J	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Sertraline.	Depression [6A70-6A7Z]	[51]
Trimipramine	DM1SC8M	Moderate	Antagonize the effect of Tacrine when combined with Trimipramine.	Depression [6A70-6A7Z]	[52]
Cyclobenzaprine	DM1YBRM	Moderate	Antagonize the effect of Tacrine when combined with Cyclobenzaprine.	Depression [6A70-6A7Z]	[52]
Imipramine	DM2NUH3	Moderate	Antagonize the effect of Tacrine when combined with Imipramine.	Depression [6A70-6A7Z]	[52]
Fluoxetine	DM3PD2C	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Fluoxetine.	Depression [6A70-6A7Z]	[51]
Nortriptyline	DM4KDYJ	Moderate	Antagonize the effect of Tacrine when combined with Nortriptyline.	Depression [6A70-6A7Z]	[52]
Escitalopram	DMFK9HG	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Escitalopram.	Depression [6A70-6A7Z]	[51]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Tacrine when combined with OPC-34712.	Depression [6A70-6A7Z]	[52]
Clomipramine	DMINRKW	Moderate	Antagonize the effect of Tacrine when combined with Clomipramine.	Depression [6A70-6A7Z]	[52]
Trazodone	DMK1GBJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Trazodone.	Depression [6A70-6A7Z]	[51]
Amoxapine	DMKITQE	Moderate	Antagonize the effect of Tacrine when combined with Amoxapine.	Depression [6A70-6A7Z]	[52]
Doxepin	DMPI98T	Moderate	Antagonize the effect of Tacrine when combined with Doxepin.	Depression [6A70-6A7Z]	[53]
Maprotiline	DMPWB7T	Moderate	Antagonize the effect of Tacrine when combined with Maprotiline.	Depression [6A70-6A7Z]	[52]
Hyoscyamine	DM804UR	Moderate	Antagonize the effect of Tacrine when combined with Hyoscyamine.	Digestive system disease [DE2Z]	[52]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Tacrine when combined with Mepenzolate.	Digestive system disease [DE2Z]	[61]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Tacrine when combined with Oxybutynine.	Discovery agent [N.A.]	[52]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[51]
Meclizine	DMS7T13	Moderate	Antagonize the effect of Tacrine when combined with Meclizine.	Dizziness and giddiness [MB48]	[52]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Deutetrabenazine.	Dystonic disorder [8A02]	[51]
Ingrezza	DMVPLNC	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Ingrezza.	Dystonic disorder [8A02]	[51]
Carbamazepine	DMZOLBI	Moderate	Antagonize the effect of Tacrine when combined with Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[52]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Cannabidiol.	Epileptic encephalopathy [8A62]	[56]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Tacrine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[52]
Tropicamide	DM1D90W	Moderate	Antagonize the effect of Tacrine when combined with Tropicamide.	Eye anterior segment structural developmental anomaly [LA11]	[61]
Solifenacin	DMG592Q	Moderate	Antagonize the effect of Tacrine when combined with Solifenacin.	Functional bladder disorder [GC50]	[52]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Tacrine when combined with Tolterodine.	Functional bladder disorder [GC50]	[52]
Darifenacin	DMWXLYZ	Moderate	Antagonize the effect of Tacrine when combined with Darifenacin.	Functional bladder disorder [GC50]	[52]
Pentamidine	DMHZJCG	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Pentamidine.	Fungal infection [1F29-1F2F]	[51]
Propantheline	DM2EN6G	Moderate	Antagonize the effect of Tacrine when combined with Propantheline.	Gastric ulcer [DA60]	[52]
Cimetidine	DMH61ZB	Moderate	Antagonize the effect of Tacrine when combined with Cimetidine.	Gastro-oesophageal reflux disease [DA22]	[52]
Sunitinib	DMCBJSR	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[51]
Cyclopentolate	DMA8LM5	Moderate	Antagonize the effect of Tacrine when combined with Cyclopentolate.	General examination [QA00]	[61]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[62]
Fostemsavir	DM50ILT	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Tacrine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[64]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Tacrine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[51]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Tacrine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[65]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Tacrine when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[52]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Tacrine when combined with ITI-007.	Insomnia [7A00-7A0Z]	[52]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Tacrine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[66]
Alosetron	DML2A03	Moderate	Decreased metabolism of Tacrine caused by Alosetron mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[67]
Clidinium	DMUMQZ0	Moderate	Antagonize the effect of Tacrine when combined with Clidinium.	Irritable bowel syndrome [DD91]	[52]
Dicyclomine	DMZSDGX	Moderate	Antagonize the effect of Tacrine when combined with Dicyclomine.	Irritable bowel syndrome [DD91]	[52]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Methotrexate.	Leukaemia [2A60-2B33]	[56]
Physostigmine	DM2N0TO	Moderate	Additive cholinergic effects by the combination of Tacrine and Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[50]
Ceritinib	DMB920Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Ceritinib.	Lung cancer [2C25]	[51]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Tacrine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[68]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Tacrine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[69]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Selpercatinib.	Lung cancer [2C25]	[49]
Lumefantrine	DM29GAD	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Lumefantrine.	Malaria [1F40-1F45]	[49]
Chloroquine	DMSI5CB	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Chloroquine.	Malaria [1F40-1F45]	[51]
Quinine	DMSWYF5	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Quinine.	Malaria [1F40-1F45]	[51]
Primaquine	DMWQ16I	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Primaquine.	Malaria [1F40-1F45]	[51]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[51]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Idelalisib.	Mature B-cell leukaemia [2A82]	[70]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[51]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Clofarabine.	Mature B-cell lymphoma [2A85]	[71]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Tacrine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[72]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Tacrine and LGX818.	Melanoma [2C30]	[73]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Tacrine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[74]
Panobinostat	DM58WKG	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Panobinostat.	Multiple myeloma [2A83]	[51]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Thalidomide.	Multiple myeloma [2A83]	[49]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Tacrine and Siponimod.	Multiple sclerosis [8A40]	[49]
Fingolimod	DM5JVAN	Moderate	Increased risk of atrioventricular block by the combination of Tacrine and Fingolimod.	Multiple sclerosis [8A40]	[75]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Tacrine and Ozanimod.	Multiple sclerosis [8A40]	[76]
Neostigmine	DM6T2J3	Moderate	Additive cholinergic effects by the combination of Tacrine and Neostigmine.	Myasthenia gravis [8C6Y]	[50]
Pyridostigmine	DM8HO1L	Moderate	Additive cholinergic effects by the combination of Tacrine and Pyridostigmine.	Myasthenia gravis [8C6Y]	[50]
Ambenonium	DMOP0BL	Moderate	Additive cholinergic effects by the combination of Tacrine and Ambenonium.	Myasthenia gravis [8C6Y]	[50]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Romidepsin.	Mycosis fungoides [2B01]	[49]
Nilotinib	DM7HXWT	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[51]
Dasatinib	DMJV2EK	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[51]
Droperidol	DM0DXA8	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Droperidol.	Nausea/vomiting [MD90]	[51]
Dimenhydrinate	DM264B3	Moderate	Antagonize the effect of Tacrine when combined with Dimenhydrinate.	Nausea/vomiting [MD90]	[52]
Prochlorperazine	DM53SRA	Moderate	Antagonize the effect of Tacrine when combined with Prochlorperazine.	Nausea/vomiting [MD90]	[52]
Promethazine	DM6I5GR	Moderate	Antagonize the effect of Tacrine when combined with Promethazine.	Nausea/vomiting [MD90]	[52]
Granisetron	DMIUW25	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Granisetron.	Nausea/vomiting [MD90]	[51]
Dolasetron	DMMG26Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Dolasetron.	Nausea/vomiting [MD90]	[51]
Ondansetron	DMOTQ1I	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Ondansetron.	Nausea/vomiting [MD90]	[51]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Tacrine and Bupropion.	Nicotine use disorder [6C4A]	[77]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Entrectinib.	Non-small cell lung cancer [2C25]	[49]
Lofexidine	DM1WXA6	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Lofexidine.	Opioid use disorder [6C43]	[51]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Tacrine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[49]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Rucaparib.	Ovarian cancer [2C73]	[51]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[49]
Flavoxate	DMKV4NL	Moderate	Antagonize the effect of Tacrine when combined with Flavoxate.	Pain [MG30-MG3Z]	[52]
Buprenorphine	DMPRI8G	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Buprenorphine.	Pain [MG30-MG3Z]	[51]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Triclabendazole.	Parasitic worm infestation [1F90]	[49]
Biperiden	DME78OA	Moderate	Antagonize the effect of Tacrine when combined with Biperiden.	Parkinsonism [8A00]	[61]
Procyclidine	DMHFJDT	Moderate	Antagonize the effect of Tacrine when combined with Procyclidine.	Parkinsonism [8A00]	[61]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Pimavanserin.	Parkinsonism [8A00]	[51]
Orphenadrine	DMW542E	Moderate	Antagonize the effect of Tacrine when combined with Orphenadrine.	Parkinsonism [8A00]	[52]
Apomorphine	DMX38HQ	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Apomorphine.	Parkinsonism [8A00]	[51]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tacrine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[78]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Tacrine and Lindane.	Pediculosis [1G00]	[79]
Ranitidine	DM0GUSX	Moderate	Antagonize the effect of Tacrine when combined with Ranitidine.	Peptic ulcer [DA61]	[52]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Tacrine when combined with Methylscopolamine.	Peptic ulcer [DA61]	[52]
Famotidine	DMRL3AB	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Famotidine.	Peptic ulcer [DA61]	[51]
Macimorelin	DMQYJIR	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[51]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Lefamulin.	Pneumonia [CA40]	[51]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Degarelix.	Prostate cancer [2C82]	[51]
Fluphenazine	DMIT8LX	Moderate	Antagonize the effect of Tacrine when combined with Fluphenazine.	Psychotic disorder [6A20-6A25]	[52]
Sorafenib	DMS8IFC	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Sorafenib.	Renal cell carcinoma [2C90]	[51]
Gatifloxacin	DMSL679	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[49]
Cyproheptadine	DM92AH3	Moderate	Antagonize the effect of Tacrine when combined with Cyproheptadine.	Rheumatoid arthritis [FA20]	[52]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Tacrine and Leflunomide.	Rheumatoid arthritis [FA20]	[51]
Quetiapine	DM1N62C	Moderate	Antagonize the effect of Tacrine when combined with Quetiapine.	Schizophrenia [6A20]	[52]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Tacrine when combined with Mesoridazine.	Schizophrenia [6A20]	[53]
Thioridazine	DM35M8J	Moderate	Antagonize the effect of Tacrine when combined with Thioridazine.	Schizophrenia [6A20]	[53]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Tacrine when combined with Aripiprazole.	Schizophrenia [6A20]	[52]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Iloperidone.	Schizophrenia [6A20]	[51]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Paliperidone.	Schizophrenia [6A20]	[51]
Loxapine	DM8AI9U	Moderate	Antagonize the effect of Tacrine when combined with Loxapine.	Schizophrenia [6A20]	[52]
Perphenazine	DMA4MRX	Moderate	Antagonize the effect of Tacrine when combined with Perphenazine.	Schizophrenia [6A20]	[52]
Molindone	DMAH70G	Moderate	Antagonize the effect of Tacrine when combined with Molindone.	Schizophrenia [6A20]	[52]
Chlorpromazine	DMBGZI3	Moderate	Antagonize the effect of Tacrine when combined with Chlorpromazine.	Schizophrenia [6A20]	[52]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Tacrine when combined with Thiothixene.	Schizophrenia [6A20]	[52]
Risperidone	DMN6DXL	Moderate	Antagonize the effect of Tacrine when combined with Risperidone.	Schizophrenia [6A20]	[52]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Asenapine.	Schizophrenia [6A20]	[51]
Pimozide	DMW83TP	Moderate	Antagonize the effect of Tacrine when combined with Pimozide.	Schizophrenia [6A20]	[52]
Vardenafil	DMTBGW8	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[51]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[56]
Epirubicin	DMPDW6T	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[51]
Vandetanib	DMRICNP	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[51]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[51]
Doxorubicin	DMVP5YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[51]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Pitolisant.	Somnolence [MG42]	[51]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[51]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Tacrine and Naltrexone.	Substance abuse [6C40]	[80]
Lenvatinib	DMB1IU4	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Lenvatinib.	Thyroid cancer [2D10]	[51]
Cabozantinib	DMIYDT4	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Cabozantinib.	Thyroid cancer [2D10]	[51]
Tizanidine	DMR2IQ4	Major	Decreased metabolism of Tacrine caused by Tizanidine mediated inhibition of CYP450 enzyme.	Tonus and reflex abnormality [MB47]	[81]
Atropine	DMEN6X7	Moderate	Antagonize the effect of Tacrine when combined with Atropine.	Unspecific substance harmful effect [NE6Z]	[52]
Triprolidine	DM7SWIA	Moderate	Antagonize the effect of Tacrine when combined with Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[52]
Carbinoxamine	DMCT31R	Moderate	Antagonize the effect of Tacrine when combined with Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[52]
Brompheniramine	DMFOVSD	Moderate	Antagonize the effect of Tacrine when combined with Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[52]
Dexbrompheniramine	DMKVWGE	Moderate	Antagonize the effect of Tacrine when combined with Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[52]
Acrivastine	DMTIGA0	Moderate	Antagonize the effect of Tacrine when combined with Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[53]
Procainamide	DMNMXR8	Moderate	Antagonize the effect of Tacrine when combined with Procainamide.	Ventricular tachyarrhythmia [BC71]	[52]
Propafenone	DMPIBJK	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[51]
Flecainide	DMSQDLE	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[51]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6687).
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] BDDCS applied to over 900 drugs
• [4] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [8] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [9] Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes. J Pharm Pharm Sci. 2014;17(3):427-38.
• [10] Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
• [11] Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
• [12] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [13] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [14] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [15] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [16] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [17] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [18] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [19] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [20] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [21] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [22] Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
• [23] Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
• [24] Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
• [25] Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
• [26] Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23.
• [27] In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
• [28] Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7.
• [29] Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
• [30] Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
• [31] Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem Biol Interact. 2005 Apr 15;152(2-3):101-6.
• [32] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [33] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [34] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [35] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [36] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [37] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [38] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [40] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [41] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [42] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [43] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [44] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [45] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [46] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [47] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [48] Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.
• [49] Cerner Multum, Inc. "Australian Product Information.".
• [50] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [51] Canadian Pharmacists Association.
• [52] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [53] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
• [54] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [55] Product Information. Cognex (tacrine). Parke-Davis, Morris Plains, NJ.
• [56] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [57] Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
• [58] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [59] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [60] Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
• [61] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
• [62] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [63] Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
• [64] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [65] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [66] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [67] Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
• [68] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [69] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [70] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [71] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [72] Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
• [73] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [74] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [75] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [76] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [77] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [78] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [79] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
• [80] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [81] Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]